Session

BLEXIT - best oncological outcomes from cystectomy

Poster Session 68

  • Location:
    Room Munich, North Hall (Level 1)
  • Chairs:
    To be confirmed
     F. Saad
     P. Zehnder, Luzern (CH)
  • Aims and objectives of this session

    This session is designed to optimise oncological outcomes.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
895
Clinical and outcome characteristics of the cancer genome atlas (TCGA) bladder cancer cohort: Is it representative?

By: Seiler R.1, Black P.2, Thalmann G.3, Stenzl A.4, Todenhöfer T.4

Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 3University of Bern, Dept. of Urology, Bern, Switzerland, 4University Hospital, Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

896
Does associated CIS with MIBC impact on neoadjuvant chemotherapy? Results of an International consortium

By: Vasdev N.1, Zagar H2, Noel J.3, Suleyman N.1, Thorpe A4, Mir M.C.6, Ercole C.E.6, Zargar-Shoshtari K.7, Fairey A.S.8, Mertens L.S.9, Dinney C.P.10, Krabbe L.M.11, Cookson M.S.12, Jacobsen N.E.13, Gandhi N.M.14, Griffin J.15, Montgomery J.S.16, Yu E.Y.17, Xylinas E.18, Campain N.J.19, Veeraterpillay R.4, Kassouf W.20, Dall’Era M.A.21, Seah J.A.22, Horenblas S.9, Sridhar S.S.22, McGrath J.S.19, Aning J.23, Shariat S.F.24, Wright J.L.17, Morgan T.M.16, Holzbeierlein J.M.15, Bivalacqua T.J.14, North S.25, Barocas D.A.26, Lotan Y.11, Garcia J.A.2, Grivas P.2, Shah J.B.10, Van Rhijn B.W.9, Daneshmand S.8, Spiess P.E.7, Li J.2, Stephenson A.J.2, Black P5

Institutes: 1Lister Hospital Stevenage, Division of Robotic Urology, Department of Urology, Stevenage, United Kingdom, 2Glickman Urological and Kidney Institute and Taussig Cancer Center, Cleveland Clinic, Cleveland, United States of America, 3Division of Robotic Surgery, Dept. of Urology, Stevenage, United Kingdom, 4Freeman Hospital, Dept. of Urology, Newcastle, United Kingdom, 5University of British Columbia , Dept. of Urologic Sciences, Vancouver, Canada, 6Cleveland Clinic, Glickman Urological and Kidney Institute and Taussig Cancer Center, Cleveland, United States of America, 7H. Lee Moffitt Cancer Center and Research Institute, Dept. of Genitourinary Oncology, Tampa, United States of America, 8University of Southern California, USC/Norris Comprehensive Cancer Center, Institute of Urology, Los Angeles, United States of America, 9The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 10MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, 11University of Texas Southwestern Medical Center, Dept. of Urology, Dallas, United States of America, 12University of Oklahoma College of Medicine, Dept. of Urology, Oklahoma City, United States of America, 13University of Alberta, Edmonton, Alberta, Canada, 14The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Dept. of Urology, Baltimore, United States of America, 15University of Kansas Medical Center, Dept. of Urology, Kansas City, United States of America, 16University of Michigan Health System, Dept. of Urology, Ann Arbor, United States of America, 17Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Researc, Dept. of Medicine, Seattle, United States of America, 18Weill Cornell Medical College, Presbyterian Hospital, Dept. of Urology, New York, United States of America, 19Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Dept. of Surgery, Exeter, United Kingdom, 20McGill University Health Center, Dept. of Surgery (Division of Urology), Montreal, Canada, 21University of California at Davis, Davis Medical Center, Dept. of Urology, Sacramento, United States of America, 22Princess Margaret Cancer Center, Dept. of Urology, Toronto, Canada, 23Freeman Hospital, Dept. of Urology, New Castle upon Tyne, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Dept. of Surgery, Exeter, United Kingdom, 24Weill Cornell Medical College, Presbyterian Hospital, New York, Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria, 25Cross Cancer Institute, Edmonton, Alberta, Canada, 26Vanderbilt University Medical Center, Dept. of Urologic Surgery, Nashville, United States of America

897
Bladder-sparing protocol consisting of low-dose chemoradiotherapy and consolidative partial cystectomy against muscle-invasive bladder cancer: A comparison of oncological outcomes between primary and progressive diseases

By: Nakamura Y., Tanaka H., Fujii Y., Inoue M., Ito M., Kijima T., Yoshida S., Yokoyama M., Ishioka J., Matsuoka Y., Saito K., Kihara K.

Institutes: Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan

898
The B4GALT1 expression is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with muscle-invasive bladder cancer

By: Xie H.1, Zhou L.2, Zhu Y.1, Wang Z.3, Fu Q.3, Zhu Y.1, Shen Y.1, Xu J.3, Ye D.1

Institutes: 1Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, 2Zhongshan Hospital, Fudan University, Dept. of Urology, Shanghai, China, 3School of Basic Medical Sciences, Fudan University, Biochemistry and Molecular Biology, Shanghai, China

899
Pattern of positive node metastases in patients treated with extended and super extended pelvic lymph node dissection and radical cystectomy due to bladder cancer

By: Moschini M.1, Colombo R.1, Suardi N.4, Burgio G.1, Bandini M.1, Zaffuto E.1, Damiano R.2, Mattei A.3, Shariat S.4, Briganti A.1, Montorsi F.1, Gallina A.1

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, 2Magna Graecia University of Catanzaro, Dept. of Urology, Catanzaro, Italy, 3Klinik Für Urologie, Luzerner Kantonsspital, Dept. of Urology, Lucerne, Switzerland, 4Medical University of Vienna, Dept. of Urology, Vienna, Austria

900
Circulating tumor cells do not correspond with clinicopathological characteristics of muscle-invasive bladder cancer patients undergoing radical cystectomy: Interim results of the CirGuidance study

By: Boormans J.L.1, De Kruijff I.2, Beije N.2, Kraan J.3, Te Slaa E.4, Wijburg C.5, Van Der Hoeven J.6, Van Der Heijden A.G.7, Somford R.8, Klaver O.S.9, Van N.M.3, Martens J.W.3, Sleijfer S.2

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Medical Oncology, Rotterdam, The Netherlands, 3Erasmus MC, Dept. of Medical Oncology and Cancer Genomics, Rotterdam, The Netherlands, 4Isala Klinieken, Dept. of Urology, Zwolle, The Netherlands, 5Rijnstate Hospital, Dept. of Urology, Arnhem, The Netherlands, 6RDGG, Dept. of Urology, Delft, The Netherlands, 7Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 8CWZ, Dept. of Urology, Nijmegen, The Netherlands, 9Maasstadziekenhuis, Dept. of Urology, Rotterdam, The Netherlands

901
Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy

By: Seiler R.1, Ashab H.A.D.2, Erho N.2, Van Rhijn B.W.3, Winters B.4, Douglas J.5, Van Kessel K.6, Fransen Van De Putte E.3, Sommerlad M.5, Wang Q.7, Choeurng V.7, Gibb E.7, Palmer-Aronsten B.7, Lam L.7, Buerki C.7, Davicioni E.7, Sjödahl G.8, Kardos J.9, Hoadley K.9, Lerner S.10, McConkey D.11, Choi W.11, Kim W.9, Kiss B.12, Thalmann G.12, Todenhöfer T.13, Crabb S.14, North S.15, Zwarthoff E.6, Boormans J.6, Wright J.4, Dall’Era M.16, Van Der Heijden M.3, Black P.13

Institutes: 1Universitätsspital Bern, Universitätsklinik für Urologie, Bern, Switzerland, 2GenomeDx, Biosciences, Vancouver, Canada, 3Netherlands Cancer Institute, Dept. of Surgical Oncology, Division of Urology, Amsterdam, The Netherlands, 4University of Washington School of Medicine, Dept. of Urology, Seattle, United States of America, 5University Hospital of Southampton, Dept. of Urology, Hampshire, United Kingdom, 6Erasmus MC, University Medical Center Rotterdam, Dept. of Pathology, Rotterdam, The Netherlands, 7GenomeDx, Dept. of Biosciences, Vancouver, Canada, 8Department of Translational Medicine, Lund University, Division of Urological Research, Malmö, Sweden, 9University of North Carolina At Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, United States of America, 10Baylor College of Medicine, Dept. of Urologic Oncology, Houston, United States of America, 11University of Texas MD Anderson Cancer Center, Dept. of Urology, Houston, United States of America, 12University of Bern, Dept. of Urology, Bern, Switzerland, 13University of British Columbia, Dept. of Urologic Sciences, Vancouver, Canada, 14University Hospital of Southampton, Dept. of Medical Oncology, Hampshire, United Kingdom, 15University of Alberta Edmonton, Cross Care Institute, Dept. of Oncology, Alberta, Canada, 16University of Sacramento, UC Davis Comprehensive Cancer Center, Sacramento, United States of America

902
Preoperative double-J stenting increases the risk of upper urinary tract (UUT) recurrence after radical cystectomy

By: Kiss B.1, Furrer M-A.1, Wuethrich P.2, Burkhard F.1, Thalmann G.1, Roth B.1

Institutes: 1University Hospital Bern, Dept. of Urology, Bern, Switzerland, 2University Hospital Bern, Dept. of Anesthesiology, Bern, Switzerland

903
Impact of perioperative transfusion of red blood cells and fresh frozen plasma on recurrence-free survival of patients after radical cystectomy for bladder cancer

By: Schubert T., Schmid M.A., Renninger M., Lütfrenk T., Stenzl A., Gakis G.

Institutes: University Hospital of Tübingen, Dept. of Urology, Tübingen, Germany

904
Fate of patients undergoing pulmonary metastasectomy for metastatic urothelial carcinoma

By: Hoshi S.1, Fukui I.2, Kageyama Y.3, Kawashima K.4, Narita S.5, Ono K.6, Numahata K.1, Sato M.8, Morozumi K.8, Kuromoto A.8, Ozawa M.8, Hoshi K.7, Bilim V.7, Sasagawa I.7

Institutes: 1Yamagata Prefectural Central Hospital, Dept. of Urology, Yamagata, Japan, 2Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, 3Saitama Prefectural Cancer Center, Dept. of Urology, Saitama, Japan, 4Tochige Prefectural Cancer Center, Dept. of Urology, Tochigi, Japan, 5Akita University Hospital, Dept. of Urology, Akita, Japan, 6Ishinomaki Redcross Hospital, Dept. of Urology, Ishinomaki, Japan, 7Yamagata Tokushykai Hospital, Dept. of Urology, Yamagata, Japan, 8Yamagata Prefectural Centaral Hospital, Dept. of Urology, Yamagata, Japan

905
Characterization of genomic aberrations of circulating, cell-free DNA in bladder cancer patients treated with radical cystectomy using multiplex ligation-dependent probe amplification: A new and efficient profiling method

By: Soave A.1, Chun F.1, Rink M.1, Weisbach L.1, Maurer V.1, Gild P.1, Steinbach B.2, Fisch M.1, Pantel K.2, Schwarzenbach H.2

Institutes: 1University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2University Medical Center Hamburg-Eppendorf, Dept. of Tumor Biology, Hamburg, Germany

906
Perioperative allogeneic blood transfusion does not adversely impact survival after radical cystectomy for urinary bladder cancer – a competing-risks analysis from a multi-institutional European series

By: Gild P.1, Vetterlein M.1, Kluth L.A.1, Gierth M.2, Fritsche H-M.2, Burger M.2, Protzel C.3, Hakenberg O.3, Von Landenberg N.4, Roghmann F.4, Noldus J.4, Nuhn P.5, Rink M.1, Chun F.1, May M.6, Fisch M.1, Aziz A.1

Institutes: 1Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 2Caritas St. Josef Medical Center, University of Regensburg, Dept. of Urology, Regensburg, Germany, 3University of Rostock, Dept. of Urology, Rostock, Germany, 4Marien Hospital Herne, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, 5University Hospital Mannheim, Dept. of Urology, Mannheim, Germany, 6St. Elisabeth Medical Center Straubing, Dept. of Urology, Straubing, Germany

907
A propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic

By: Kulkarni G.1, Hermanns T.1, Wei Y.1, Bhindi B.1, Satkunasivam R.1, Athanasopoulos P.1, Bostrom P.1, Kuk C.2, Li K.1, Templeton A.3, Sridhar S.3, Van Der Kwast T.4, Chung P.5, Bristow R.5, Milosevic M.5, Warde P.5, Fleshner N.6, Jewett M.6, Bashir S.7, Zlotta A.8

Institutes: 1Princess Margaret Cancer Centre, University Health Network, Dept. of Surgery, Toronto, Canada, 2Mount Sinai Hospital, Dept. of Surgery, Toronto, Canada, 3Princess Margaret Cancer Centre, University Health Network, Dept. of Medical Oncology, Toronto, Canada, 4Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, 5Princess Margaret Hospital, University Health Network, Radiation Medicine Program, Toronto, Canada, 6Princess Margaret Cancer Centre, University Health Network, Dept. of Surgery (urology), Toronto, Canada, 7Princess Margaret Cancer Centre, University Health Network, Dept. of Biostatistics, Toronto, Canada, 8Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada

908
Outcome of patients undergoing radical cystectomy for urothelial cell carcinoma of the bladder with evidence of distant metastases. Results of a single center study

By: Grimm T., Buchner A., Schneevoigt B-S., Kretschmer A., Grabbert M., Jokisch F., Schulz G., Stief C.G., Karl A.

Institutes: LMU-Klinikum der Universität München, Dept. of Urology, Munich, Germany

909
The accuracy of sequential urethral frozen sections and its impact on urethral recurrence after radical cystectomy

By: Schubert T., Schmid M.A., Renninger M., Lütfrenk T., Stenzl A., Gakis G.

Institutes: University Hospital of Tübingen, Dept. of Urology, Tübingen, Germany